Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …

As part of a multicenter study evaluating homologous and heterologous COVID-19 booster
vaccines, we assessed the magnitude, breadth, and short-term durability of binding and …

Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting
with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger …

Background Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed.
Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory …

Objectives Multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa have
become a global problem, often leaving the polymyxins as therapeutic agents of last resort. …

We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna
mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen …